Beneficial effect of bezafibrate on primary sclerosing cholangitis (three case reports)

American Journal of Gastroenterology

Volumn 97, Issue 7, 2002, Pages 1849-1851

  Kita, Ryuichi ^a,b   Kita Sasai, Yuri ^a   Hanaoka, Ikuko ^a   Kimura, Toru ^a   Kokuryu, Hiroyuki ^a   Takamatsu, Seigo ^a   Osaki, Yukio ^a   Tomono, Naomi ^a   Hachiya, Tsutomu ^a   Shimizu, Tatsuo ^a  

^a Osaka Red Cross Hospital ^*

^b OSAKA RED CROSS HOSPITAL   (Japan)

^c Aiseikai Yamashina Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; BEZAFIBRATE; GAMMA GLUTAMYLTRANSFERASE; SALAZOSULFAPYRIDINE; URSODEOXYCHOLIC ACID;

ADULT; AGED; CASE REPORT; COLONOSCOPY; DRUG EFFECT; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; LETTER; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 0036318091     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(02)04225-9     Document Type: Letter

References (9)

1. Medical treatment of primary sclerosing cholangitis
2. Ursodiol for primary sclerosing cholangitis
3. Tacrolimus (FK506), a treatment for primary sclerosing cholangitis: Results of an open-label preliminary trial
4. The effect of bezafibrate treatment on serum alkaline phosphatase isozyme activities
5. Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis
6. Effect of bezafibrate in the treatment of primary biliary cirrhosis
7. The PPARα-leukotriene B4 pathway to inflammation control
8. Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease
9. Recent status of primary sclerosing cholangitis in Japan